- Condition: Depressive Disorder, Major
Interventions: Drug: LuAA21004; Drug: Duloxetine; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Conditions: Depression; Coronary Heart Disease
Interventions: Other: Usual Care; Behavioral: Collaborative Care
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: AZD6765 iv; Drug: AZD6765 iv; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Condition: Acute Depressive Episode
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg; Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained-release 50 mg/day; Drug: desvenlafaxine succinate sustained-release 100 mg/day; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Major Depressive Disorder With Mixed Features
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Device: NEST-1 (NeoSync EEG Synchronized TMS); Device: SHAM
Sponsors: NeoSync, Inc.; NeoSync, Inc.
Recruiting - verified May 2012 - Condition: Cancer
Interventions: Drug: prasterone; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Treatment Outcome
Interventions: Drug: Lu AA21004; Drug: Escitalopram
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Conditions: Colorectal Neoplasms; Colonic Polyps; Colorectal Cancer
Intervention: Device: Technically Improved High Definition NBI Colonoscopy System
Sponsors: VA Palo Alto Health Care System; VA Palo Alto Health Care System; Kansas City Veteran Affairs Medical Center
Recruiting - verified January 2012 - Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Intervention: Drug: Escitalopram
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified February 2012 - Condition: Major Depressive Disorder (MDD)
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Intervention: Procedure: Whole-body Cooling
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2012 - Condition: Treatment Refractory Depression
Interventions: Drug: Ketamine; Drug: Clonidine; Drug: placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine; University of Miami
Not yet recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Hepatitis C; Depression
Intervention: Other: Depression collaborative care model
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified December 2011 - Condition: Depression
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Conditions: Heart Failure; Depression
Interventions: Behavioral: Cognitive Behavior Therapy; Other: Heart Failure Self-care Education
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Major Depression; Treatment
Interventions: Drug: Sertraline; Behavioral: Cognitive Behavioral Therapy
Sponsors: National Institute of Mental Health (NIMH); National Institute of Mental Health (NIMH)
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Intervention: Drug: escitalopram and adjunctive aripiprazole and placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified August 2011 - Conditions: Bipolar; Depression
Intervention: Drug: lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Conditions: Parkinson's Disease; Depression; Anxiety
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institutes of Health (NIH)
Recruiting - verified November 2011 - Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram; Drug: Sertraline; Drug: Venlafaxine XR
Sponsors: BRC Operations Pty. Ltd.; BRC Operations Pty. Ltd.
Recruiting - verified March 2012 - Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified February 2012 - Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Interventions: Procedure: Hypothermia; Procedure: Normothermic Control
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified September 2011
 |
Join Clinical Trials in Missouri for Depression |
